Note: This feature on the best-selling pharmaceuticals of 2023 was updated on March 27. Changes are possible as more data become available. Sales of drugs with more than one developer are added together (as in the case of the COVID-19 vaccine Comirnaty) unless one of those companies records the net sales for it, i.e., Dupixent.…
Lilly’s mirikizumab beats placebo in pivotal ulcerative colitis trial
Eli Lilly and Company (NYSE:LLY) announced that its interleukin-23 subunit p19 inhibitor mirikizumab achieved its primary endpoint of clinical remission at 52 weeks in the Phase 3 LUCENT-2 study. Lilly says mirikizumab is the first anti-IL23p19 to demonstrate maintenance of clinical remission in a Phase 3 ulcerative colitis study. Janssen (NYSE:JNJ) has ongoing clinical trials…